Search results
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Added:
3 years ago
Abstract
Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase…
View more
Added:
7 months ago
Join the Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) and Dr Milton Packer (Baylor University Medical Center, US) for a thought-provoking discussion on the present and future of heart failure care at ESC Congress 2023.
In this unique exchange, Dr Packer shares his thoughts on heart failure guidelines and the '2023 Focused Update of the 2021 ESC Guidelines for the…
View more
Added:
10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Added:
1 year ago
Heart failure management: Where are we now?
Dip into the new heart failure data presented at ESC-HF Conference 2022. Learn more about the latest research and treatment options delivered by researchers driving the field.Short, accessibleExpert Interviewswill be available with select faculty focusing on the results, applicability, and impact on future research.
Join globally renown faculty as…
View more
Added:
3 years ago
Chronic heart failure is common, disabling and deadly. It affects approximately five million people in the US and accounts for over one million hospitalizations annually.1 Despite continued improvements in heart failure therapy, mortality over five years is approximately 50%.2 This article summarizes significant recent developments in pharmacologic and device therapy for heart failure.
…
View more
Added:
1 year ago
In this short video we asked Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) about the key heart failure highlights of 2022 and his thoughts on what comes next in HF treatment and research.
Recorded at Heart Failure 2022, Madrid.
View more
Added:
6 years ago
Gemma Figtree discusses the CANVAS trial - canagliflozin and heart failure in type 2 diabetes mellitus.
Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Added:
3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly…
View more
Added:
3 years ago
The prevalence of heart failure and the resultant mortality has continued to rise despite increased understanding of the pathogenesis and improvement in management strategies.1 Left ventricular (LV) dysfunction is the final stage of most primary cardiovascular diseases, and greater severity is directly correlated with worse prognosis. The principal manifestation of heart failure progression is a…
View more
« First